SCHEMBL26739734

SCHEMBL26739734

CNc1ccc(N2CCC(F)(F)CC2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.43
▸ GAA P10253 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.40
▸ ADRA1A P35348 1/20 0.40
▸ DGAT1 O75907 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ RAB9A P51151 3/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TRPV3 Q8NET8 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KCNQ3 O43525 1/20 0.38
▸ KCNQ2 O43526 1/20 0.38
▸ CNR2 P34972 1/20 0.37
▸ CLK2 P49760 1/20 0.37
▸ DYRK1A Q13627 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26739737 0.82 CLK2 (0.39) MAPTGAAKDM4EALDH1A1CRBN
SCHEMBL26739746 0.82 MAPT (0.45) MAPTGAAKDM4EALDH1A1RAB9A
SCHEMBL4082936 0.82 KCNQ3 (0.48) MAPTGAAKDM4EALDH1A1RAB9A
SCHEMBL13006763 0.80 MAPT (0.49) MAPTGAAKDM4EALDH1A1KCNQ3
SCHEMBL12845203 0.79 RAB9A (0.57) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL12858975 0.79 GRIN2D (0.49) MAPTGAAKDM4EALDH1A1ADRA1A
SCHEMBL23446016 0.78 CNR2 (0.46) MAPTGAAKDM4EALDH1A1DGAT1
SCHEMBL2790485 0.78 MAPT (0.58) MAPTGAAKDM4EALDH1A1DGAT1
SCHEMBL22279042 0.76 P4HTM (0.47) MAPTGAAKDM4EALDH1A1SMN1; SMN2
SCHEMBL23107193 0.76 PANK3 (0.42) ADRA1ATRPV3CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 — — US disclosed
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS MONTE ROSA THERAPEUTICS AG (CH) 2024-07-04 — — US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
US-11912682-B2 Isoindolinone compounds MONTE ROSA THERAPEUTICS, INC. (US) 2024-02-27 — — US disclosed
US-20230348418-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2023-11-02 — — US disclosed
US-20230348418-A1 ISOINDOLINONE COMPOUNDS MONTE ROSA THERAPEUTICS AG (CH) 2023-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240216355-A1 PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS UPF1, NSUN2, RTF2 MAPT 4671/4885GAA 1519/4885KDM4E 3979/4885
US-20230348418-A1 ISOINDOLINONE COMPOUNDS CYP4F2, AOC2, AOC3 MAPT 4795/4885GAA 3652/4885KDM4E 3578/4885
US-11912682-B2 Isoindolinone compounds CYP4F2, AOC2, AOC3 MAPT 4795/4885GAA 3687/4885KDM4E 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback